Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2024-N-3271]
 AGENCY: Food and Drug Administration, HHS.
 ACTION: Notice.
 SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of two abbreviated new drug applications (ANDAs) from the holder of those ANDAs. The basis for the withdrawal is that the ANDA holder has repeatedly failed to file required annual reports for those ANDAs.
 DATES: Approval is withdrawn as of December 31, 2024.
 FOR FURTHER INFORMATION CONTACT: Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, 
                        ( print page 107147)
                        Silver Spring, MD 20993-0002, 301-796-3471, 
                        *Martha.Nguyen@fda.hhs.gov.*


SUPPLEMENTARY INFORMATION: The holder of an approved application to market a new drug for human use is required to submit annual reports to FDA concerning its approved application in accordance with §§ 314.81 and 314.98 (21 CFR 314.81 and 314.98). In the 
                    **Federal Register**
                     of August 8, 2024 (89 FR 64936), FDA published a notice offering an opportunity for a hearing (NOOH) on a proposal to withdraw approval of two ANDAs because the holder of these ANDAs had repeatedly failed to submit the required annual reports for these ANDAs. The holder of these ANDAs did not respond to the NOOH. Failure to file a written notice of participation and request for hearing as required by § 314.200 (21 CFR 314.200) constitutes a waiver of the opportunity for hearing by the holder of the ANDAs concerning the proposal to withdraw approval of the ANDAs and a waiver of any contentions concerning the legal status of the drug products. Therefore, FDA is withdrawing approval of the two applications listed in table 1 of this document. Table 1—Approved ANDAs for Which Required Reports Have Not Been Submitted
Application No.
Drug
ApplicantANDA 207309
Metronidazole tablet, 250 milligrams (mg) and 500 mg
Flamingo Pharmaceuticals Ltd., U.S. Agent for Flamingo Pharmaceuticals Ltd., 1125 Gaither Rd., Rockville, MD 20850.ANDA 207938
Piroxicam capsule, 10 mg and 20 mg
Do.
 FDA finds that the holder of the ANDAs listed in table 1 has repeatedly failed to submit reports required by §§ 314.81 and 314.98. In addition, under § 314.200, FDA finds that the holder of the ANDAs has waived its opportunity for a hearing and any contentions concerning the legal status of the drug products. Therefore, based on these findings and pursuant to the authority under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)), approval of the ANDAs listed in table 1 and all amendments and supplements thereto, is hereby withdrawn, as of December 31, 2024. Dated: December 23, 2024. P. Ritu Nalubola, Associate Commissioner for Policy.


[FR Doc. 2024-31360 Filed 12-30-24; 8:45 am] BILLING CODE 4164-01-P